We coalesce preclinical and human laboratory models to examine stress-related biobehavioral mechanisms in addiction medicine.
Our current work focuses on the noradrenergic system, stress-associated peptides and the hypothalamic-pituitary-adrenal (HPA) axis.
We formed a bench-to-bedside program to facilitate the interaction between basic research, human laboratory studies and clinical trials for the development of novel therapeutics to treat addictive disorders.
Haass-Koffler et al, Defining the role of corticotropin releasing factor binding protein in alcohol consumption. Translational Psychiatry, 2016
Our team is affiliated with the: